Has structural bioinformatics advanced enough to form the core of a drug discovery program? A new generation of companies exploiting structure-focused technologies is counting on it.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldstein, J.L. Remarks at the Awards Ceremony, Albert Lasker Award for Clinical Research, 1999. http://www.laskerfoundation.org/awards/library/ 1999remarksgsclin2.shtml
Shuker, S.B. et al. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531–1534 (1996).
Palczewski, K. et al. Crystal structure of rhodopsin: a G protein–coupled receptor. Science 289, 739–745 (2000).
Levinthal, C. How to fold graciously. in Mössbauer Spectroscopy in Biological Systems. Proceedings of a Meeting Held at Allerton House, Monticello, Illinois. (eds. DeBrunner, J.T.P. & Munck, E.) 22–24 (University of Illinois Press, Chicago, IL, USA, 1969).
Williams, P. et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424, 464–468 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thiel, K. Structure-aided drug design's next generation. Nat Biotechnol 22, 513–519 (2004). https://doi.org/10.1038/nbt0504-513
Issue Date:
DOI: https://doi.org/10.1038/nbt0504-513
This article is cited by
-
Insight into ligand selectivity in HCV NS5B polymerase: molecular dynamics simulations, free energy decomposition and docking
Journal of Molecular Modeling (2010)
